BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27016236)

  • 21. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
    Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
    Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.
    da Silva EM; Fix DJ; Sebastiao APM; Selenica P; Ferrando L; Kim SH; Stylianou A; Da Cruz Paula A; Pareja F; Smith ES; Zehir A; Konner JA; Cadoo K; Reis-Filho JS; Abu-Rustum NR; Mueller JJ; Weigelt B; Park KJ
    Mod Pathol; 2021 Aug; 34(8):1570-1587. PubMed ID: 33772212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.
    Tao J; Sun D; Zhou H; Zhu J; Zhang X; Hou H
    Pathol Res Pract; 2022 Oct; 238():154074. PubMed ID: 35988354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular testing of NSCLC using a platform for rapid detection of multiple oncogenetic mutations.
    Cate F; Itani D; Vnencak-Jones C; Johnson J; Coogan A
    J Am Soc Cytopathol; 2014; 3(6):327-330. PubMed ID: 31051723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of molecular testing in clinical practice in gynecologic cancers.
    Huang M; Hunter T; Slomovitz B; Schlumbrecht M
    Cancer Med; 2019 May; 8(5):2013-2019. PubMed ID: 30848097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
    Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
    Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
    Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
    PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.
    Tirodkar TS; Budiu RA; Elishaev E; Zhang L; Mony JT; Brozick J; Edwards RP; Vlad AM
    PLoS One; 2014; 9(7):e102409. PubMed ID: 25078979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
    Sa JK; Hwang JR; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim J; Kim MS; Paik ES; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee Y; Her NG; Shin YJ; Cho HJ; Kim JY; Seo YJ; Koo H; Oh JW; Lee T; Kim HS; Song SY; Bae JS; Park WY; Han HD; Ahn HJ; Sood AK; Rabadan R; Lee JK; Nam DH; Lee JW
    Genome Biol; 2019 Nov; 20(1):253. PubMed ID: 31771620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
    Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
    Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.
    O'Donnell E; Mahindra A; Yee AJ; Nardi V; Birrer N; Horick N; Borger D; Finkelstein D; Iafrate JA; Raje N
    EBioMedicine; 2015 Jan; 2(1):71-3. PubMed ID: 26137536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.
    Testa U; Petrucci E; Pasquini L; Castelli G; Pelosi E
    Medicines (Basel); 2018 Feb; 5(1):. PubMed ID: 29389895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
    Mitri ZI; Parmar S; Johnson B; Kolodzie A; Keck JM; Morris M; Guimaraes AR; Beckett BR; Borate U; Lopez CD; Kemmer KA; Alumkal JJ; Beer TM; Corless CL; Mills GB; Gray JW; Bergan RC
    J Transl Med; 2018 Dec; 16(1):358. PubMed ID: 30551737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
    Nasioudis D; Fernandez ML; Wong N; Powell DJ; Mills GB; Westin S; Fader AN; Carey MS; Simpkins F
    Gynecol Oncol; 2023 Oct; 177():86-94. PubMed ID: 37657193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):155-163. PubMed ID: 30683261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic insights in gynecologic cancer.
    Roddy E; Chapman J
    Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic profiling of gynecologic cancers and implications for clinical practice.
    Prendergast EN; Elvin JA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):18-25. PubMed ID: 27984344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation and utilization of the molecular tumor board to guide precision medicine.
    Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
    Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.
    Davidson B; Holth A; Lindemann K; Zahl Eriksson AG; Nilsen TA; Torgunrud A
    Virchows Arch; 2024 May; ():. PubMed ID: 38733380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusion genes in gynecologic tumors: the occurrence, molecular mechanism and prospect for therapy.
    Lu B; Jiang R; Xie B; Wu W; Zhao Y
    Cell Death Dis; 2021 Aug; 12(8):783. PubMed ID: 34381020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.